Ep. 382 - Summer’s venture wave; drugging beta-catenin; Capricor & FDA
From BioCentury This Week · · 25 min
This plays from the publisher's own server. We do not host a copy.
Description
A baker’s dozen of biotechs shrugged off the summer haze to raise nearly $800 million in venture cash. On the latest BioCentury This Week podcast, BioCentury’s analysts discuss (https://www.biocentury.com/article/660475) the financings, which included money for a potential challenger to Amgen’s blockbuster Tepezza and a new venture (https://www.biocentury.com/article/660480) from immunology professor Georg Schett with backing from Deerfield Management, Boulevard Bio. The analysts also discuss new approaches (https://www.biocentury.com/article/660442) to drug cancer’s “undruggable” β-catenin pathway, and whether Capricor’s latest regulatory move (https://www.biocentury.com/article/660495) will give Duchenne muscular dystrophy therapy deramiocel new life at FDA.
View full story: https://www.biocentury.com/article/660539
#BiotechFinancing #DrugDevelopment #BetaCatenin #DuchenneMuscularDystrophy #Biopharma
00:00 - Introduction 02:18 - Venture Rounds 12:02 - Drugging β-catenin 18:12 - Capricor & FDA
To submit a question to BioCentury’s editors, email the BioCentury This Week team at podcasts@biocentury.com.
Reach us by sending a text (https://www.buzzsprout.com/1035190/fan_mail/new)